

# Weekly Evidence Report

Health Technology Assessment Philippines



13 - 19 August 2022

## Overview

The following report presents summaries of evidence the Department of Health (DOH) - Health Technology Assessment (HTA) Division reviewed for the period of 13-19 August 2022. The HTA Division reviewed a total of 12 studies for the said period.

Evidence includes **1** study on Epidemiology; **2** studies on Vaccines; **1** study on Drugs; **1** studies on Transmission; **3** studies on Equipment and Devices; **0** studies on Medical and Surgical Procedures; **0** studies on Traditional Medicine; **4** studies on Preventive & Promotive Health; and **0** studies on Other Health Technologies.



## Sections

Epidemiology

Vaccines

Drugs

Preventive & Promotive Health

Transmission

Equipment & Devices

Medical & Surgical Procedures

Traditional Medicine

Other Health Technologies

## Evidence on Epidemiology

### Local COVID-19 Case Tracker:

[https://doh.gov.ph/2019-nCoV?gclid=CjwKCAjwjtOTBhAvEiwASG4bCOmLzFMQljh8DX\\_VVSGA-HmO0Pt5\\_CscykID7xZv4zqIXG5vm9PM2xoC27QQAxD\\_BwE](https://doh.gov.ph/2019-nCoV?gclid=CjwKCAjwjtOTBhAvEiwASG4bCOmLzFMQljh8DX_VVSGA-HmO0Pt5_CscykID7xZv4zqIXG5vm9PM2xoC27QQAxD_BwE)

Date	Author/s	Title	Journal/ Article Type	Summary
17 August 2022	WHO Global	<a href="#">Weekly epidemiological update on COVID-19 - 17 August 2022</a>	<i>WHO Global Situation Report</i>	<ul style="list-style-type: none"> <li>Globally, the number of new weekly cases decreased by 24% during the week of 8 to 14 August 2022, as compared to the previous week, with over 5.4 million new cases reported (Figure 1, Table 1). The number of new weekly deaths decreased by 6%, as compared to the previous week, with over 15 000 fatalities reported.</li> <li>As of 14 August 2022, 587 million confirmed cases and 6.4 million deaths have been reported globally.</li> </ul>

## Evidence on Vaccines

### WHO COVID-19 Vaccine Tracker:

<https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>

### WHO SAGE Vaccine Recommendations:

<https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization>

**Local COVID-19 Vaccine Updates:** <https://doh.gov.ph/vaccines>

Date	Author/s	Title	Journal/ Article Type	Summary
11 August 2022	Centers for Disease Control and Prevention	<a href="#">COVID-19 Science Update released: August 20, 2021 Edition 103</a>	<i>US CDC/ Case Report</i>	<ul style="list-style-type: none"> <li>Among solid organ transplant recipients who had received 2 doses of mRNA-1273 (Moderna) vaccine, a 3rd dose produced significantly higher immunogenicity than placebo.</li> <li>Adolescents vaccinated with 2 doses of mRNA-1273 had immunogenicity and vaccine efficacy comparable to young adults, with no serious adverse events noted.</li> </ul>
18 August 2022	Hakki et al	<a href="#">Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset</a>	<i>The Lancet Respiratory Medicine / Prospective, Longitudinal, Community cohort study</i>	<ul style="list-style-type: none"> <li>Less than a quarter of COVID-19 cases shed infectious virus before symptom onset; under a crude 5-day self-isolation period from symptom onset, two-thirds of cases released into the community would still be infectious, but with reduced infectious viral shedding.</li> <li>Infectious virus kinetic modelling suggested that the initial rate of viral replication determines the course of infection and infectiousness.</li> </ul>

## Evidence on Drugs

Date	Author/s	Title	Journal/ Article Type	Summary
18 August 2022	Bramante et al	<a href="#">Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19</a>	<i>The New England Journal of Medicine / Randomized Clinical Trial</i>	<ul style="list-style-type: none"> <li>None of the three medications that were evaluated prevented the occurrence of hypoxemia, an emergency department visit, hospitalization, or death associated with Covid-19.</li> </ul>

## Evidence on Preventive &amp; Promotive Health

## Evidence on Personal Measures

Date	Author/s	Title	Journal/ Article Type	Summary
13 August 2022	Drzymalla et al	<a href="#">COVID-19-related health outcomes in people with primary immunodeficiency</a>	<i>Elsevier Public Health Emergency Collection / Systematic Review</i>	<ul style="list-style-type: none"> <li>A better understanding of COVID-19 in people with primary immunodeficiency (PI), rare inherited defects in the immune system, is important for protecting this population, especially as population-wide approaches to mitigation change.</li> <li>As prolonged infections might increase the likelihood of genetic variants emerging, SARS-CoV2 isolates from people with PI and extended illness would be good candidates to prioritize for whole genome sequencing.</li> </ul>

## Evidence on Community Measures

Date	Author/s	Title	Journal/ Article Type	Summary
19 August 2022	Masetti et al	<a href="#">Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems — United States</a>	<i>US CDC / Case Report</i>	<ul style="list-style-type: none"> <li>High levels of immunity and availability of effective COVID-19 prevention and management tools have reduced the risk for medically significant illness and death.</li> <li>To prevent medically significant COVID-19 illness and death, persons must understand their risk, take steps to protect themselves and others with vaccines, therapeutics, and nonpharmaceutical interventions when needed, receive testing and wear masks when exposed, receive testing if symptomatic, and isolate for <math>\geq 5</math> days if infected.</li> </ul>

## Evidence on Preventive & Promotive Health (cont.)

### Evidence on Screening

Date	Author/s	Title	Journal/ Article Type	Summary
17 August 2022	Santos Faioes, et.al.	<a href="#">HIV infection does not affect the risk of death of COVID-19 patients: A systematic review and meta-analysis of epidemiological studies</a>	<i>Global Health /Systematic Review</i>	<ul style="list-style-type: none"> <li>Although our meta-analysis suggests no difference in the risk of death of PLHIV with SARS-CoV-2 infection, if compared with HIV-seronegative patients, further research should be encouraged to improve the current knowledge about the impact of SARS-CoV-2 and HIV co-infection.</li> </ul>
Date	Author/s	Title	Journal/ Article Type	Summary
11 August 2022	Hughes et al.	<a href="#">COVID-19 collaborative modelling for policy response in the Philippines, Malaysia and Vietnam</a>	<i>The Lancet Regional Health Western Pacific/ Cross-sectional study</i>	<ul style="list-style-type: none"> <li>Like many countries around the world, they have experienced a high burden of transmission and infection following the emergence of the Delta and Omicron variants</li> <li>Changes in factors such as variants, disease dynamics, and vaccine coverage is leading to a shift in COVID-19 public health response policy</li> </ul>

### Evidence on Transmission

Date	Author/s	Title	Journal/ Article Type	Summary
17 August 2022	Mtetwa et al.	<a href="#">Genetic diversity and spread dynamics of SARS-CoV-2 variants present in African populations</a>	<i>BioRxiv/ Case Report</i>	<ul style="list-style-type: none"> <li>South Africa, Kenya, and Nigeria as key sources of viral transmissions between Sub-Saharan African nations because they had the most SARS-CoV-2 genomes sampled and sequenced.</li> <li>The pandemic breakout revealed that current land-border regulations aimed at limiting virus's international transmission are ineffective and a lot needs to be done to implement and improve our African land-borders as far as epidemiology is concerned in order to contain such outbreaks in the future</li> </ul>

## Evidence on Transmission (cont.)

Date	Author/s	Title	Journal/ Article Type	Summary
18 August 2022	Hakki et al	<a href="#">Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset</a>	<i>The Lancet Respiratory Medicine Journal / Prospective, Longitudinal, Community cohort study</i>	<ul style="list-style-type: none"> <li>Less than a quarter of COVID-19 cases shed infectious virus before symptom onset; under a crude 5-day self-isolation period from symptom onset, two-thirds of cases released into the community would still be infectious, but with reduced infectious viral shedding</li> </ul>

## Evidence on Equipment and Devices

Date	Author/s	Title	Journal/ Article Type	Summary
15 August 2022	Patel et al	<a href="#">Effect of corticosteroid therapy on mortality in COVID-19 patients</a>	<i>Wiley Online Library: Reviews in Medical Virology / Systematic Review and Meta-Analysis</i>	<ul style="list-style-type: none"> <li>Corticosteroid therapy produced a negative prognosis as depicted by increased mortality among COVID-19 patients</li> <li>The possible reasons might be delay in virus clearance and secondary infections due to corticosteroids initiated at high dose in the early stage of infection.</li> </ul>

Date	Author/s	Title	Journal/ Article Type	Summary
17 August 2022	Schrom et al	<a href="#">Field assessment of BinaxNOW antigen tests as COVID-19 treatment entry point at a community testing site in San Francisco during evolving omicron surges</a>	<i>medRVix / Cohort Study</i>	<ul style="list-style-type: none"> <li>BinaxNOW detected high viral load from anterior nasal swabs consistently across omicron sublineages emerging between January and June of 2022.</li> <li>Simulations support BinaxNOW as an entry point for COVID-19 treatment in a community field setting.</li> </ul>

## Evidence on Equipment and Devices (cont.)

Date	Author/s	Title	Journal/ Article Type	Summary
18 August 2022	Hansom et al	<a href="#">IDSA Guidelines on the Diagnosis of COVID-19: Serologic Testing</a>	<i>Infectious Disease Society of America / Case report</i>	<ul style="list-style-type: none"> <li>Information on the clinical performance and utility of SARS-CoV-2 serologic tests are rapidly emerging. Based on available evidence, detection of anti-SARS-CoV-2 antibodies may be useful for confirming the presence of current or past infection in selected situations</li> <li>The panel identified three potential indications for serologic testing including: 1) evaluation of patients with a high clinical suspicion for COVID-19 when molecular diagnostic testing is negative and at least two weeks have passed since symptom onset; 2) assessment of multisystem inflammatory syndrome in children; and 3) for conducting serosurveillance studies</li> <li>The panel identified three potential indications for serologic testing including: 1) evaluation of patients with a high clinical suspicion for COVID-19 when molecular diagnostic testing is negative and at least two weeks have passed since symptom onset; 2) assessment of multisystem inflammatory syndrome in children; and 3) for conducting serosurveillance studies</li> </ul>

## Evidence on Medical and Surgical Procedures

Date	Author/s	Title	Journal/ Article Type	Summary
–	–	–	–	–

## Evidence on Traditional Medicine

Date	Author/s	Title	Journal/ Article Type	Summary
–	–	–	–	–

## Evidence on Other Health Technologies

Date	Author/s	Title	Journal/ Article Type	Summary
–	–	–	–	–